This new booster dose will be recommended during the new vaccination campaign in conjunction with the flu vaccination campaign.
The High Office of Health (HAS) is giving the green light to three Omicron-modified Covid-19 vaccines for a new booster vaccination campaign planned for the fall and linked to the flu campaign, it announced on Tuesday 20
This new booster dose will be recommended to people at risk of severe form, their environment and carers. HAS recommends “either one of the three bivalent vaccines– two developed by Pfizer/BioNTech, the third by Moderna – recently validated by the European Medicines Agency.
“Vaccines Adapted to Circulating Strains”
“Based on the available data and in an epidemic context marked by the majority circulation of the BA.5 subvariant“, HAS recommends using “best» one of these vaccines, all with messenger RNA, for the new fall booster. This recommendation applies regardless of the Covid vaccine that person was originally given.
“Like seasonal flu vaccines, which are updated annually to account for the viruses most likely to circulate during the winter, bivalent mRNA vaccines are not new vaccines, but vaccines adapted to circulating strains.“, emphasizes HAS in its press release.
These are the Moderna and Pfizer/BioNTech vaccines targeting the original strain of the virus and the Omicron BA.1 variant, and the Pfizer/BioNTech vaccine targeting the original strain and the BA .4 and BA.5 subvariants from Omicron.
Infection cases on the rise
HAS also stands by its recommendation to combine the Covid-19 booster vaccination campaign with the flu vaccination, which will start on 18 October. A simultaneous injection or the same day of both vaccines is possible, he recalls.
“In the near future and because the number of infection cases started to rise again for several days» this health authority recommends not postponing the second booster dose to persons over 60 and under 60 at risk of a severe form who did not receive it within the recommended time frame. It resembles the effectiveness of current vaccines (monovalent) against severe forms of Covid-19.
SEE ALSO – Covid-19: Moderna sues Pfizer and BioNTech for vaccine patent infringement